SCHEMBL240915

SCHEMBL240915

O=c1[nH]c2cc(O)ccc2o1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 4/20 0.61
NOS3 P29474 3/20 0.61
NOS2 P35228 3/20 0.61
LMNA P02545 1/20 0.61
CYP1A2 P05177 1/20 0.61
ADRA2A P08913 1/20 0.61
TSHR P16473 1/20 0.61
THPO P40225 1/20 0.61
BLM P54132 1/20 0.61
NPSR1 Q6W5P4 1/20 0.61
OGT O15294 1/20 0.53
PDE3B Q13370 1/20 0.53
PDE3A Q14432 1/20 0.53
POLB P06746 1/20 0.51
KMO O15229 1/20 0.50
CDK5 Q00535 3/20 0.45
CDK5R1 Q15078 3/20 0.45
DYRK1A Q13627 2/20 0.45
CA12 O43570 1/20 0.44
MCL1 Q07820 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30282769 1.00 NOS1 (0.61) NOS1NOS3NOS2LMNACYP1A2
Formic Acid SCHEMBL31731276 0.93 NOS1 (0.54) NOS1NOS3NOS2LMNACYP1A2
SCHEMBL241569 0.84 NOS1 (0.61) NOS1NOS3NOS2LMNACYP1A2
SCHEMBL30863879 0.84 NOS1 (0.61) NOS1NOS3NOS2LMNACYP1A2
SCHEMBL10897160 0.78 PSMB8 (0.63) LMNAPOLBCDK5CDK5R1CA12
Chlorzoxazone SCHEMBL35178 0.76 NOS1 (1.00) NOS1NOS3NOS2LMNACYP1A2
SCHEMBL5543509 0.76 NOS1 (0.61) NOS1NOS3NOS2LMNACYP1A2
SCHEMBL243203 0.76 NOS1 (1.00) NOS1NOS3NOS2LMNACYP1A2
Chlorzoxazone SCHEMBL29720120 0.76 NOS1 (1.00) NOS1NOS3NOS2LMNACYP1A2
SCHEMBL221802 0.76 NOS1 (0.61) NOS1NOS3NOS2LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0026474-B1 COMPOSITION AND PROCESS FOR OXIDATIVE DYEING OF HAIR Wella Aktiengesellschaft (DE) 1983-06-08 EP claimed
EP-0026474-A1 Composition and process for oxidative dyeing of hair Wella Aktiengesellschaft (DE) 1981-04-08 EP claimed
WO-1981000811-A1 MEANS AND PROCESS ALLOWING HAIR COLORATION BY OXIDATION WELLA AG (DE) 1981-04-02 WO claimed
US-20250353855-A1 HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2025-11-20 US disclosed
CN-118055930-A Thiadiazole derivative, composition and application thereof 北京丹擎医药科技有限公司 2024-05-17 CN disclosed
US-11584717-B2 MIF modulators YALE UNIVERSITY (US) 2023-02-21 US disclosed
US-20200377457-A1 MIF MODULATORS UNIV YALE (US) 2020-12-03 US disclosed
US-20190270706-A1 MIF MODULATORS UNIV YALE (US) 2019-09-05 US disclosed
US-20190233441-A1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2019-08-01 US disclosed
US-20190233441-A1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2019-08-01 US disclosed
EP-3041841-B1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF HOFFMANN LA ROCHE (CH) 2019-06-05 EP disclosed
EP-0592511-B1 SEQUENCE-SPECIFIC BINDING POLYMERS FOR DUPLEX NUCLEIC ACIDS ANTIVIRALS INC (US) 1997-08-20 EP disclosed
EP-0719258-A1 CYCLIC AMIDE DERIVATIVES FOR PROTECTING AGAINST ULTRAVIOLET RAYS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1996-07-03 EP disclosed
WO-1996002508-A1 CYCLIC AMIDE DERIVATIVES FOR PROTECTING AGAINST ULTRAVIOLET RAYS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1996-02-01 WO disclosed
EP-0669927-A1 SEQUENCE-SPECIFIC BINDING POLYMERS FOR DUPLEX NUCLEIC ACIDS ANTIVIRALS INC. (US) 1995-09-06 EP disclosed
US-5405938-A Hydrogen bonding an N-heterocyclic-substituted ribose-based polymer to a double-stranded DNA to block genetic activity, to diagnose for pathogens and to aid in genetic engineering ANTI-GENE DEVELOPMENT GROUP (US) 1995-04-11 US disclosed
WO-1994012517-A1 SEQUENCE-SPECIFIC BINDING POLYMERS FOR DUPLEX NUCLEIC ACIDS ANTIVIRALS INC. (US) 1994-06-09 WO disclosed
US-5166315-A Polynucleotides for genetic engineering ANTI-GENE DEVELOPMENT GROUP (US) 1992-11-24 US disclosed
US-4620850-A HYDROXYBENZOLFURANONE WELLA AKTIENGESELLSCHAFT (DE) 1986-11-04 US disclosed
EP-0026474-B1 COMPOSITION AND PROCESS FOR OXIDATIVE DYEING OF HAIR Wella Aktiengesellschaft (DE) 1983-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584717-B2 MIF modulators MIF, HMGB2, HMGB3 NOS1 492/4885NOS3 486/4885NOS2 283/4885
US-20200377457-A1 MIF MODULATORS MIF, HMGB2, HMGB3 NOS1 492/4885NOS3 486/4885NOS2 283/4885
US-20190233441-A1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF ABL1, JAK2, JAK1 NOS1 1454/4885NOS3 1257/4885NOS2 1102/4885
US-20250353855-A1 HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, FH NOS1 4380/4885NOS3 3810/4885NOS2 4030/4885
US-20190270706-A1 MIF MODULATORS MIF, HMGB2, HMGB3 NOS1 492/4885NOS3 486/4885NOS2 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.